Reducing bladder medication in Parkinson's disease
Part of Brain & nervous system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether gradually reducing or stopping certain bladder medications (called antimuscarinics) can improve symptoms in people with Parkinson's disease. If you qualify, you might get a different bladder medication (like mirabegron) as part of the study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 60 years of age or older.
- You must have a Parkinson's disease diagnosis from a movement disorder specialist.
- You must have been taking a bladder medication (like oxybutynin, tolterodine, or solifenacin) for overactive bladder for at least 3 months.
- You must be able to sign consent forms and fill out online surveys, and be reachable by phone or video call.
- You must not have severe liver or kidney disease, untreated very high blood pressure, or frequent urinary tract infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares vaginal estradiol (a hormone placed in the vagina) versus an oral beta-3 medicine called mirabegron for overactive bladder symptoms. It looks to see which treatment works better and is safer for postmenopausal women.
This study tests whether behavioral therapy (like bladder training and pelvic floor exercises) alone, or combined with a medication called mirabegron, is better at improving bladder symptoms (like sudden urges and frequent urination) in people with Parkinson's disease. The goal is to see which approach helps reduce urgency and improve daily life.
This study tests medicines to reduce “urgency” urine leakage (when you suddenly feel you must go) and to see whether improving bladder control also helps overall mental and physical health. You may be eligible if you have had these symptoms for at least 3 months and can follow the study plan.
This trial looks at whether simple blood tests can predict how well women with overactive bladder will respond to a medicine called mirabegron. If you have had symptoms for at least 3 months and your doctor plans to start mirabegron, this study may help tailor your treatment.
This trial tests whether pyridostigmine can improve constipation symptoms in people with Parkinson’s disease. If you have Parkinson’s and functional constipation (with infrequent bowel movements), this study may offer a new medication option and closely track your bowel function.
This trial is testing whether it is safe to slowly reduce or stop anticholinergic medications (benztropine or trihexyphenidyl) in people with schizophrenia. It aims to see if stopping these drugs can help with thinking and memory without causing worsening movement problems.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.